Cargando…
SAT-561 Effects of Mineralocorticoid Receptor Antagonists on Primary Aldosteronism Screening
Background: Mineralocorticoid receptor antagonists (MRAs) are the mainstay of medical therapy for primary aldosteronism (PA), and MRAs also benefit patients with other forms of resistant hypertension and cardiovascular disorders. MRAs impact the renin-angiotensin-aldosterone system (RAAS), raising c...
Autores principales: | Tezuka, Yuta, Turcu, Adina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7209325/ http://dx.doi.org/10.1210/jendso/bvaa046.248 |
Ejemplares similares
-
SAT-564 Effectiveness of Treatment with Mineralocorticoid Receptor Antagonistsin Primary Aldosteronism
por: Tezuka, Yuta, et al.
Publicado: (2020) -
Real-World Effectiveness of Mineralocorticoid Receptor Antagonists in Primary Aldosteronism
por: Tezuka, Yuta, et al.
Publicado: (2021) -
SAT-067 Insights into Paradoxical Bilateral Aldosterone Suppression in the Adrenal Veins of Patients with Primary Aldosteronism
por: Wannachalee, Taweesak, et al.
Publicado: (2019) -
PSUN68 Finerenone for Primary Aldosteronism: A Novel Mineralocorticoid Receptor Antagonist
por: Aurora, John, et al.
Publicado: (2022) -
SAT-061 Determinants of Cosyntropin Effect on Adrenal Vein Sampling Lateralization in Primary Aldosteronism
por: Wannachalee, Taweesak, et al.
Publicado: (2019)